Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
2017 · New England Journal of Medicine · 5,655 citations
https://doi.org/10.1056/nejmoa1707447
Y
Yi Lin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.0K
Papers
38.5K
Citations
78
h-index
318
i10-index
Yi Lin is an academic researcher from South China Agricultural University. The author has contributed to research in topics: CAR-T cell therapy research & Multiple Myeloma Research and Treatments & Lymphoma Diagnosis and Treatment. The author has an h-index of 78, co-authored 852 publications.
ORCID: 0000-0002-1556-6416Papers by this author
worksChimeric antigen receptor T-cell therapy — assessment and management of toxicities
2017 · Nature Reviews Clinical Oncology · 2,279 citations
https://doi.org/10.1038/nrclinonc.2017.148
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
2021 · New England Journal of Medicine · 2,258 citations
https://doi.org/10.1056/nejmoa2024850
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
2019 · New England Journal of Medicine · 1,675 citations
https://doi.org/10.1056/nejmoa1817226
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
2021 · The Lancet · 1,543 citations
https://doi.org/10.1016/s0140-6736(21)00933-8
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
2021 · The Lancet · 721 citations
https://doi.org/10.1016/s0140-6736(21)01222-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat